We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Implanted Pump Improves Pain Management

By HospiMedica staff writers
Posted on 06 Jun 2002
A study has demonstrated that an implanted pump that delivers pain medication by slow release into the spinal fluid reduces pain and improves survival in cancer patients, compared to oral painkillers. More...
The study was presented at the annual meeting of the American Society of Clinical Oncology in Orlando (FL, USA).

More than 200 patients with a variety of cancers took part in the study, conducted by researchers at Johns Hopkins (Baltimore, MD, USA; www.hopkinsmedicine.org) and other medical centers. All of the patients had pain that broke through morphine or other opiate drugs. They were randomly assigned to either receive an implantable pump to deliver medication directly into the spinal fluid or to continue taking pain medicine by mouth. At the end of six months, 54% of the pump patients were living vs 37% of those on oral medications. Moreover, the pump patients had less pain and fewer side effects from the pain drugs, less fatigue, less constipation or nausea, and improved mental status.

The pump used in the study is surgically implanted in the abdomen. A small tube from the pump reaches around the waist to deliver medication directly into the spinal fluid. Doctors can tailor the dosage to suit each patient and can refill the pump by injecting medication through the abdomen into a tiny opening on the front of the device. The pump was developed by Medtronic, Inc. (Minneapolis, MN, USA).

"This challenges our thinking about how to treat cancer pain,” said Peter S. Staats, M.D., director of the division of pain medicine at Johns Hopkins and a co-principal investigator for the study. "This suggests that earlier intervention with an approach that minimizes systemic drugs has a significant benefit in a variety of domains.”




Related Links:
Johns Hopkins

New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Hybrid Arch Device
Neo EDE
New
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.